0000000000289210

AUTHOR

Lothar Müller

showing 5 related works from this author

Cetuximab plus cisplatin–5-fluorouracil versus cisplatin–5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a ra…

2009

Abstract Background This study assessed the activity of the mAb cetuximab in combination with cisplatin and 5-fluorouracil (5-FU) in advanced esophageal squamous cell carcinoma. Patients and methods For a maximum of six 29-day cycles, patients received cisplatin 100 mg/m2, day 1, plus 5-FU 1000 mg/m2, days 1–5 (CF), either alone or in combination with cetuximab (CET–CF; 400 mg/m2 initial dose followed by 250 mg/m2 weekly thereafter). The primary end point was tumor response. Tumor material was obtained for analysis of KRAS mutation status. Results Sixty-two eligible patients were included, 32 receiving CET–CF and 30 CF. Cetuximab did not exacerbate grade 3/4 toxicity, except for rash (6% ve…

AdultDiarrheaMalemedicine.medical_specialtyNeutropeniaTime FactorsEsophageal NeoplasmsCetuximabPhases of clinical researchKaplan-Meier EstimateAntibodies Monoclonal Humanizedmedicine.disease_causeGastroenterologyDisease-Free SurvivalInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProgression-free survivalAgedCross-Over StudiesDose-Response Relationship DrugCetuximabbusiness.industryAntibodies MonoclonalNauseaHematologyMiddle AgedCombined Modality TherapySurvival AnalysisChemotherapy regimenSurgeryTreatment OutcomeOncologyEpidermoid carcinomaFluorouracilResponse Evaluation Criteria in Solid TumorsCarcinoma Squamous CellFemaleFluorouracilKRASCisplatinbusinessFollow-Up Studiesmedicine.drugAnnals of Oncology
researchProduct

Compassionate Use of Sorafenib in Relapsed and Refractory Flt3-ITD Positive Acute Myeloid Leukemia.

2009

Abstract Abstract 2060 Poster Board II-37 Introduction: The Flt3-internal tandem duplication can be found in up to 30% of all acute myeloid leukemia (AML) patients and confers a poor risk status characterized by an increased relapse rate and poor overall survival. Moreover, Flt3-ITD-positive AML patients relapsing after allogenic stem cell transplantation (SCT) have very limited therapeutic options. Sorafenib is a multikinase inhibitor that is approved for the treatment of metastatic renal cell and hepatocellular carcinoma. Besides targeting Raf, the platelet derived growth factor receptor (PDGFR) and the vascular endothelial growth factor receptor (VEGFR) it has also significant inhibitory…

OncologySorafenibmedicine.medical_specialtyChemotherapybusiness.industrymedicine.medical_treatmentImmunologyInduction chemotherapyMyeloid leukemiaCell BiologyHematologymedicine.diseaseBiochemistryTransplantationmedicine.anatomical_structureTolerabilityhemic and lymphatic diseasesHepatocellular carcinomaInternal medicinemedicineBone marrowbusinessmedicine.drugBlood
researchProduct

Geriatric assessment and biomarkers in patients with metastatic breast cancer receiving first-line mono-chemotherapy: Results from the randomized pha…

2017

Abstract Objectives To determine predictive/prognostic factors for patients with metastatic breast cancer (MBC) receiving first-line monochemotherapy using biomarker analysis and geriatric assessment (GA). Materials and Methods Karnofsky Performance Status (KPS) and GA as clinical parameters, and prognostic inflammatory and nutritional index (PINI), and Glasgow prognostic score (GPS) as biomarkers were analyzed for association with clinical outcome within the randomized phase III PEg-LIposomal Doxorubicin vs. CApecitabin iN MBC (PELICAN) trial of first-line pegylated liposomal doxorubicin (PLD) or capecitabine. Results Of 210 patients, 38% were > 65 years old. GA (n = 152) classified 74% as…

0301 basic medicineOncologymedicine.medical_specialtyMultivariate analysisAnthracyclinemedicine.medical_treatmentBreast NeoplasmsPolyethylene GlycolsCapecitabine03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansDoxorubicinKarnofsky Performance StatusGeriatric AssessmentCapecitabineAgedChemotherapyFrailtybusiness.industryAge FactorsGeriatric assessmentMiddle Agedmedicine.diseaseMetastatic breast cancer030104 developmental biologyTreatment OutcomeOncologyDoxorubicin030220 oncology & carcinogenesisDisease ProgressionBiomarker (medicine)FemaleGeriatrics and GerontologybusinessBiomarkersmedicine.drugJournal of geriatric oncology
researchProduct

1978

For the three different cases (R=polybutadiene, polypropylene oxide and EPDM) the isothermal cloud point curves of the system styrene/polystyrene/rubber (S/PS/R) show that at 25°C a decomposition into two phases occurs already in the presence of a few percents of polystyrene and rubber. By separating the phases (centrifuge) and analysis of coexisting phases, tie lines and thus critical points could be fixed. Evaluation of the results was made on the basis of the Flory and Huggins theory by means of approximations given for such systems by Scott. The interaction parameters resulting for 25°C are well in agreement with literature data—as far as available. By means of the approximations mentio…

chemistry.chemical_compoundPolybutadienechemistryNatural rubbervisual_artPolymer chemistryvisual_art.visual_art_mediumPhysical chemistryGeneral Materials SciencePolystyreneTernary operationStyreneAngewandte Makromolekulare Chemie
researchProduct

Multicenter, Observational Study of Lanreotide Autogel for the Treatment of Patients with Neuroendocrine Tumors in Routine Clinical Practice in Germa…

2021

Abstract Background The long-acting somatostatin analog lanreotide autogel is effective in the treatment of patients with neuroendocrine tumors. Objective To evaluate the long-term treatment response in patients with neuroendocrine tumors receiving lanreotide autogel in routine clinical practice. Methods Non-interventional, 24-month study in patients with neuroendocrine tumors treated with lanreotide autogel (NCT01840449). Results Patients (n=80) from 26 centers in Germany and Austria were enrolled. Neuroendocrine tumors were mainly grade 1/2, metastasized, intestinal, and associated with carcinoid syndrome; 88.9% had received previous neuroendocrine tumor treatment. Of those, 84.4% had pre…

MaleOncologymedicine.medical_specialtyEndocrinology Diabetes and Metabolismchromogranin AMedizindiarrheacarcinoid syndromeOctreotideAntineoplastic Agents030209 endocrinology & metabolismNeuroendocrine tumorsPeptides CyclicArticleflushing03 medical and health sciences0302 clinical medicineEndocrinologyQuality of lifeGermanyInternal medicineOutcome Assessment Health CareInternal MedicinemedicineClinical endpointHumansAgedMalignant Carcinoid Syndromebiologybusiness.industryChromogranin AGeneral MedicineMiddle Agedmedicine.diseaseNeuroendocrine Tumorsquality of lifeTolerabilityAustria030220 oncology & carcinogenesisbiology.proteinFemaleObservational studySomatostatinbusinessCarcinoid syndromemedicine.drugExperimental and Clinical Endocrinology & Diabetes
researchProduct